PURPOSE: IFN-alpha is a pleiotropic cytokine possessing immunomodulatory properties that may improve the efficacy of therapeutic cancer vaccines. The aim of this study was to evaluate the effectiveness and compatibility of combining recombinant IFN-alpha with poxvirus vaccines targeting the human carcinoembryonic antigen (CEA) in murine models of colorectal and pancreatic adenocarcinomas, where CEA is a self-antigen. EXPERIMENTAL DESIGN: The phenotypic and functional effects of IFN-alpha were evaluated in the draining inguinal lymph nodes of tumor-free mice. We studied the effect of the site of IFN-alpha administration (local versus distal) on antigen-specific immune responses to poxvirus vaccination. Mechanistic studies were conducted to assess the efficacy of IFN-alpha and CEA-directed poxvirus vaccines in tumor-bearing CEA transgenic mice. RESULTS: We identified a dose and schedule of IFN-alpha that induced a locoregional expansion of the draining inguinal lymph nodes and improved cellular cytotoxicity (natural killer and CD8(+)) and antigen presentation. Suppression of the vaccinia virus was avoided by administering IFN-alpha distal to the site of vaccination. The combination of IFN-alpha and vaccine inhibited tumor growth, improved survival, and elicited CEA-specific CTL responses in mice with CEA(+) adenocarcinomas. In mice with pancreatic tumors, IFN-alpha slowed tumor growth, induced CTL activity, and increased CD8(+) tumor-infiltrating lymphocytes. CONCLUSIONS: These data suggest that IFN-alpha can be used as a biological response modifier with antigen-directed poxvirus vaccines to yield significant therapeutic antitumor immune responses. This study provides the rationale and mechanistic insights to support a clinical trial of this immunotherapeutic strategy in patients with CEA-expressing carcinomas.
PURPOSE:IFN-alpha is a pleiotropic cytokine possessing immunomodulatory properties that may improve the efficacy of therapeutic cancer vaccines. The aim of this study was to evaluate the effectiveness and compatibility of combining recombinant IFN-alpha with poxvirus vaccines targeting the humancarcinoembryonic antigen (CEA) in murine models of colorectal and pancreatic adenocarcinomas, where CEA is a self-antigen. EXPERIMENTAL DESIGN: The phenotypic and functional effects of IFN-alpha were evaluated in the draining inguinal lymph nodes of tumor-free mice. We studied the effect of the site of IFN-alpha administration (local versus distal) on antigen-specific immune responses to poxvirus vaccination. Mechanistic studies were conducted to assess the efficacy of IFN-alpha and CEA-directed poxvirus vaccines in tumor-bearing CEAtransgenic mice. RESULTS: We identified a dose and schedule of IFN-alpha that induced a locoregional expansion of the draining inguinal lymph nodes and improved cellular cytotoxicity (natural killer and CD8(+)) and antigen presentation. Suppression of the vaccinia virus was avoided by administering IFN-alpha distal to the site of vaccination. The combination of IFN-alpha and vaccine inhibited tumor growth, improved survival, and elicited CEA-specific CTL responses in mice with CEA(+) adenocarcinomas. In mice with pancreatic tumors, IFN-alpha slowed tumor growth, induced CTL activity, and increased CD8(+) tumor-infiltrating lymphocytes. CONCLUSIONS: These data suggest that IFN-alpha can be used as a biological response modifier with antigen-directed poxvirus vaccines to yield significant therapeutic antitumor immune responses. This study provides the rationale and mechanistic insights to support a clinical trial of this immunotherapeutic strategy in patients with CEA-expressing carcinomas.
Authors: L Santodonato; M Ferrantini; F Palombo; L Aurisicchio; P Delmastro; N La Monica; S Di Marco; G Ciliberto; M X Du; M W Taylor; F Belardelli Journal: Cancer Gene Ther Date: 2001-01 Impact factor: 5.987
Authors: John Schmitz; Eva Reali; James W Hodge; Arti Patel; Garland Davis; Jeffrey Schlom; John W Greiner Journal: Cancer Res Date: 2002-09-01 Impact factor: 12.701
Authors: Connie L Sivinski; Karl G Kohlgraf; Michelle L VanLith; Keita Morikane; Richard M Tempero; Michael A Hollingsworth Journal: Cancer Immunol Immunother Date: 2002-05-04 Impact factor: 6.968
Authors: Howard L Kaufman; Seunghee Kim-Schulze; Kelledy Manson; Gail DeRaffele; Josephine Mitcham; Kang Seok Seo; Dae Won Kim; John Marshall Journal: J Transl Med Date: 2007-11-26 Impact factor: 5.531
Authors: Srinivas Jayanthi; Bhanu prasanth Koppolu; Sean G Smith; Rashmi Jalah; Jenifer Bear; Margherita Rosati; George N Pavlakis; Barbara K Felber; David A Zaharoff; Thallapuranam Krishnaswamy Suresh Kumar Journal: Protein Expr Purif Date: 2014-08-11 Impact factor: 1.650
Authors: Lei L Chen; Xinjian Chen; Haesun Choi; Hongxun Sang; Leo C Chen; Hongbo Zhang; Launce Gouw; Robert H Andtbacka; Benjamin K Chan; Christopher K Rodesch; Arnie Jimenez; Pedro Cano; Kimberly A Jones; Caroline O Oyedeji; Tom Martins; Harry R Hill; Jonathan Schumacher; Carlynn Willmore; Courtney L Scaife; John H Ward; Kathryn Morton; R Lor Randall; Alexander J Lazar; Shreyaskumar Patel; Jonathan C Trent; Marsha L Frazier; Patrick Lin; Peter Jensen; Robert S Benjamin Journal: Cancer Immunol Immunother Date: 2011-12-24 Impact factor: 6.968